This article is a correction to:
MIS-C Treatment: Is IVIG Always Necessary?
Francesco Licciardi1,2
Letizia Baldini3*
Marta Dellepiane1
Carlotta Covizzi3
Roberta Mogni3
Giulia Pruccoli1
Cecilia Orsi4
Ivana Rabbone4
Emilia Parodi1,2
Federica Mignone1,2
Davide Montin1,2- 1Department of Pediatrics and Public Health, Università degli Studi di Torino, Turin, Italy
- 2Ospedale Infantile Regina Margherita, Città della Salute e della Scienza, Turin, Italy
- 3Postgraduate School of Pediatrics, Università degli Studi di Torino, Turin, Italy
- 4Department of Health Sciences, University of Piemonte Orientale, Novara, Italy
A Corrigendum on
MIS-C Treatment: Is IVIG Always Necessary?
by Licciardi, F., Baldini, L., Dellepiane, M., Covizzi, C., Mogni, R., Pruccoli, G., Orsi, C., Rabbone, I., Parodi, E., Mignone, F., and Montin, D. (2021). Front. Pediatr. 9:753123. doi: 10.3389/fped.2021.753123
In the original article, there was an error. Incorrect reference numbers and authors names were cited in the text. “2, 9, 12” has been updated to “2, 11, 13,” “…ICU stay (11); Del Borrello et al. and Sacco et al. found…” has been updated to “…ICU stay; Son et al. found…,” and “9, 12” has been updated to “2, 11.”
A correction has been made to Discussion, Paragraph Number 3:
“So far, three real-life retrospective studies have been conducted regarding the use of steroids to treat MIS-C (2, 11, 13). In two of them, the authors compared the outcomes of the patients treated with steroids and IVIG vs. IVIG alone. Ouldali et al. found that adding MP to IVIG led to a significant decrease of hemodynamic support needs and a reduction in length of ICU stay; Son et al. found that the patients treated with steroids and IVIG had a lower risk of new or persistent cardiovascular dysfunction compared to the ones treated with IVIG alone (2, 11).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: MIS-C, SARS-CoV-2, therapy, IVIG (intravenous immunoglobulin) administration, steroid
Citation: Licciardi F, Baldini L, Dellepiane M, Covizzi C, Mogni R, Pruccoli G, Orsi C, Rabbone I, Parodi E, Mignone F and Montin D (2022) Corrigendum: MIS-C Treatment: Is IVIG Always Necessary? Front. Pediatr. 9:826518. doi: 10.3389/fped.2021.826518
Received: 30 November 2021; Accepted: 01 December 2021;
Published: 14 February 2022.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2022 Licciardi, Baldini, Dellepiane, Covizzi, Mogni, Pruccoli, Orsi, Rabbone, Parodi, Mignone and Montin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Letizia Baldini, letizia.baldini2@gmail.com